Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1975 1
1977 2
1981 2
1982 2
1983 2
1984 3
1985 4
1986 2
1987 4
1988 3
1989 2
1990 10
1991 3
1992 2
1993 4
1994 9
1995 9
1996 8
1997 6
1998 9
1999 8
2000 4
2001 4
2002 11
2003 10
2004 9
2005 16
2006 9
2007 15
2008 16
2009 14
2010 17
2011 7
2012 23
2013 20
2014 17
2015 22
2016 12
2017 15
2018 20
2019 15
2020 12
2021 11
2022 17
2023 7

Text availability

Article attribute

Article type

Publication date

Search Results

375 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users.
Baandrup L, Ebdrup BH, Rasmussen JØ, Lindschou J, Gluud C, Glenthøj BY. Baandrup L, et al. Cochrane Database Syst Rev. 2018 Mar 15;3(3):CD011481. doi: 10.1002/14651858.CD011481.pub2. Cochrane Database Syst Rev. 2018. PMID: 29543325 Free PMC article. Review.
Alpidem decreased the proportion of participants with benzodiazepine discontinuation (1 study, 25 participants; RR 0.41, 95% CI 0.17 to 0.99; number needed to treat for an additional harmful outcome (NNTH) 2.3 participants; low-quality evidence) and increased the occurrence of wi …
Alpidem decreased the proportion of participants with benzodiazepine discontinuation (1 study, 25 participants; RR 0.41, 95% CI 0.17 to 0.99 …
Memantine in moderate-to-severe Alzheimer's disease.
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ; Memantine Study Group. Reisberg B, et al. N Engl J Med. 2003 Apr 3;348(14):1333-41. doi: 10.1056/NEJMoa013128. N Engl J Med. 2003. PMID: 12672860 Free article. Clinical Trial.
BACKGROUND: Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. ...
BACKGROUND: Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. .. …
L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.
Jain A, Sharma BC, Mahajan B, Srivastava S, Kumar A, Sachdeva S, Sonika U, Dalal A. Jain A, et al. Hepatology. 2022 May;75(5):1194-1203. doi: 10.1002/hep.32255. Epub 2021 Dec 21. Hepatology. 2022. PMID: 34822189 Clinical Trial.
BACKGROUND AND AIMS: Data on the use of intravenous L-ornithine L-aspartate (LOLA) in the treatment of overt HE (OHE) is limited. We evaluated the role of intravenous LOLA in patients of cirrhosis with OHE grade III-IV. ...
BACKGROUND AND AIMS: Data on the use of intravenous L-ornithine L-aspartate (LOLA) in the treatment of overt HE (OHE) is limited. We …
Clinical effects of low-dose esketamine for anaesthesia induction in the elderly: A randomized controlled trial.
Li J, Wang Z, Wang A, Wang Z. Li J, et al. J Clin Pharm Ther. 2022 Jun;47(6):759-766. doi: 10.1111/jcpt.13604. Epub 2022 Jan 11. J Clin Pharm Ther. 2022. PMID: 35018643 Clinical Trial.
WHAT IS KNOWN AND OBJECTIVE: Esketamine is an N-methyl-D-aspartic acid (NMDA) receptor antagonist, which has stronger sedative and analgesic effects and fewer adverse events than ketamine. ...
WHAT IS KNOWN AND OBJECTIVE: Esketamine is an N-methyl-D-aspartic acid (NMDA) receptor antagonist, which has stronger sedative …
The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.
Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez ML, Huledal G, Kolly C, Lüönd RM, Machauer R, Veenstra SJ, Hurth K, Rueeger H, Tintelnot-Blomley M, Staufenbiel M, Shimshek DR, Perrot L, Frieauff W, Dubost V, Schiller H, Vogg B, Beltz K, Avrameas A, Kretz S, Pezous N, Rondeau JM, Beckmann N, Hartmann A, Vormfelde S, David OJ, Galli B, Ramos R, Graf A, Lopez Lopez C. Neumann U, et al. EMBO Mol Med. 2018 Nov;10(11):e9316. doi: 10.15252/emmm.201809316. EMBO Mol Med. 2018. PMID: 30224383 Free PMC article. Clinical Trial.
Combination pharmacotherapy for the treatment of neuropathic pain in adults.
Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Chaparro LE, et al. Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD008943. doi: 10.1002/14651858.CD008943.pub2. Cochrane Database Syst Rev. 2012. PMID: 22786518 Free PMC article. Review.
MAIN RESULTS: We identified 21 eligible studies: four (578 participants) evaluated the combination of an opioid with gabapentin or pregabalin; two (77 participants) evaluated an opioid with a tricyclic antidepressant; one (56 participants) of gabapentin and nortriptyline; one (12 …
MAIN RESULTS: We identified 21 eligible studies: four (578 participants) evaluated the combination of an opioid with gabapentin or pregabali …
Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D. Egan MF, et al. N Engl J Med. 2018 May 3;378(18):1691-1703. doi: 10.1056/NEJMoa1706441. N Engl J Med. 2018. PMID: 29719179 Free PMC article. Clinical Trial.
375 results